Immune and targeted therapy represent innovative therapy options in oncology.
An overview of novel immune and targeted therapy options in urologic oncology presented at the most recent scientific urological and oncological meetings is given by representatives of the German Association of Immune and Targeted Therapy (DGFIT). Besides renal cell cancer, where targeted therapy is well established, new immune and targeted approaches in prostate and bladder cancer are discussed, summarizing current results and new developments with relevant impact for the treating physician.
Written by:
Hegele A, Heinzer H, Rüttinger D, Siebels M. Are you the author?
Chirurgischen Klinik und Poliklinik Grosshadern, Klinikum der Universität München, Germany.
Reference: Aktuelle Urol. 2012 Jul;43(4):219-26.
PubMed Abstract
PMID: 23035262
Article in German.
UroToday.com Renal Cancer Section
